Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. (Record no. 30657324)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02069 a2200541 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250518085339.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 202010s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1095-6859 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1016/j.ygyno.2020.01.037 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | O'Malley, David M |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20201030 |
| 245 00 - TITLE STATEMENT | |
| Title | Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Gynecologic oncology |
| Date of publication, distribution, etc. | 05 2020 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 379-385 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adult |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged, 80 and over |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antibodies, Monoclonal, Humanized |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Combined Chemotherapy Protocols |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Bevacizumab |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Carcinoma, Ovarian Epithelial |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Resistance, Neoplasm |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Folate Receptor 1 |
| General subdivision | immunology |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Immunoconjugates |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Maytansine |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Organoplatinum Compounds |
| General subdivision | pharmacology |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Ovarian Neoplasms |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Progression-Free Survival |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Matulonis, Ursula A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Birrer, Michael J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Castro, Cesar M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gilbert, Lucy |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Vergote, Ignace |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Martin, Lainie P |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mantia-Smaldone, Gina M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Martin, Antonio González |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bratos, Raquel |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Penson, Richard T |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Malek, Karim |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Moore, Kathleen N |
| 773 0# - HOST ITEM ENTRY | |
| Title | Gynecologic oncology |
| Related parts | vol. 157 |
| -- | no. 2 |
| -- | p. 379-385 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1016/j.ygyno.2020.01.037">https://doi.org/10.1016/j.ygyno.2020.01.037</a> |
| Public note | Available from publisher's website |
No items available.